Indian healthtech startup CURAPOD has raised Rs 20 crore in a pre-Series A funding round, marking a significant step forward in its mission to modernise pain management through technology-driven, non-invasive solutions. The funding round was led by early-stage venture firm V3 Ventures, with participation from 3i Partners and Ideaspring Capital.
The fresh capital is expected to support CURAPOD’s next phase of growth as it focuses on expanding product innovation, strengthening market presence, and scaling its operations both in India and overseas.
Building Technology-Led Solutions for Pain Relief
Founded in 2022 by Sri Velliyur and Surya Maguluri, CURAPOD operates under Litemed India and is focused on developing wearable medical devices aimed at addressing everyday pain and chronic musculoskeletal conditions. The startup’s core offering is designed for people suffering from back pain, knee pain, muscle stiffness, sports injuries, joint discomfort, and other common physical ailments.
CURAPOD’s device leverages photobiomodulation therapy, a scientifically backed approach that uses red and near-infrared light to reduce inflammation, improve blood circulation, and support cellular repair. Unlike conventional pain relief methods that often rely heavily on medication, CURAPOD’s solution offers a drug-free, non-invasive alternative suited for daily use.
Funding to Accelerate Product and Market Expansion
With this Rs 20 crore infusion, the company plans to significantly enhance its product capabilities by investing in research and development. A portion of the capital will also be directed towards improving the user experience through its companion mobile application, enabling more personalised and data-driven pain management.
Additionally, CURAPOD aims to expand its manufacturing capacity, streamline supply chains, and strengthen its direct-to-consumer distribution channels. The company is also working on expanding its presence across online marketplaces, physiotherapy centres, hospitals, fitness facilities, and sports rehabilitation networks.
Eyes on Global Markets Alongside India Growth
While India remains a key focus market, CURAPOD has also set its sights on international expansion, particularly in regulated global healthcare markets. The startup plans to use the funding to explore partnerships and compliance pathways in regions such as Europe, where demand for clinically validated, wearable pain management devices continues to grow.
This dual focus on domestic depth and global reach positions CURAPOD as a brand aiming to move beyond a niche wellness label to a recognised healthtech player.
Investor Confidence in Pain Management Technology
Investors backing the round expressed confidence in CURAPOD’s technology-led approach and the large untapped potential of the pain management segment. Chronic pain is increasingly recognised as a major health concern worldwide, creating demand for solutions that balance clinical effectiveness with ease of use.
The investors believe CURAPOD’s blend of clinical credibility, wearable design, and consumer accessibility gives it the potential to become a strong player in the evolving medical devices ecosystem.
A Growing Healthtech Opportunity in India
CURAPOD’s successful pre-Series A round reflects a broader trend of rising investment interest in Indian healthtech startups, particularly those working at the intersection of medical science and consumer technology. As awareness around preventive healthcare, rehabilitation, and long-term pain relief grows, startups offering practical and evidence-backed solutions are gaining traction.
With fresh funding in place, CURAPOD is now preparing for a critical scale-up phase, aiming to make advanced pain management more accessible while redefining how Indians and global consumers manage everyday pain.